Uses
Pirepemat (IRL752) fumarate is a corticalpreferring catecholamine- and cognition-promoting agent. Pirepemat fumarate is used for the study of Parkinson's disease[1][2].
Biological Activity
Pirepemat (IRL752) fumarate is a corticalpreferring catecholamine- and cognition-promoting agent. Pirepemat fumarate is used for the study of Parkinson's disease[1][2].
IRL752 fumarate displays its highest in vitro affinities for 5-HT and NA-related targets[2].
IRL752 (3.7-100 μmol/kg, s.c.) fumarate has no significant effect on acute hyper-dopaminergic or hypo-glutamatergic motor responses, but reverses deficits resulting from hypomonoaminergic function[2].
in vivo
IRL752 (3.7-100 μmol/kg, s.c.) fumarate has no significant effect on acute hyper-dopaminergic or hypo-glutamatergic motor responses, but reverses deficits resulting from hypomonoaminergic function[2].
| Animal Model: | Normal rats[2] |
| Dosage: | 3.7-100 μmol/kg |
| Administration: | S.c., 30 min prior to testing |
| Result: | Induced dose-dependent and regio-selective alterations in brain monoamine transmission indices and gene expression.
|
References
[1]. Ipsen and IRLAB Enter Exclusive Worldwide Licensing Agreement Aimed to Improve the Lives of People Living with Parkinson's Disease. [2]. S Hjorth, et al. (3 S)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine (IRL752) -a Novel Cortical-Preferring Catecholamine Transmission- and Cognition-Promoting Agent. J Pharmacol Exp Ther. 2020 Sep;374(3):404-419.
